Ratings by Goldman Sachs (Andrea Newkirk)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 1/13/2026 | Revolution | RVMD | Maintain | Buy (N/A) |
|
Details | ||
| 9/30/2025 | Schrodinger | SDGR | New Coverage | Neutral (N/A) |
19.30 (14.93) |
-22.64% | Details | |
| 7/15/2025 | Revolution | RVMD | New Coverage | Buy (N/A) |
38.02 (155.99) |
310.28% | Details | |
| 7/15/2025 | Alkermes | ALKS | New Coverage | Buy (N/A) |
30.28 (42.76) |
41.22% | Details | |
| 7/15/2025 | Iovanace Biotherapeutics | IOVA | Downgrade | Sell (Buy) |
1.87 (3.79) |
102.67% | Details | |
| 3/14/2025 | 89bio Inc. | ETNB | New Coverage | Neutral (N/A) |
8.35 (14.84) |
77.72% | Details |
